1 Guan, W. J. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 382, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).
2 Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 323, 1239-1242, doi:10.1001/jama.2020.2648 (2020).
3 Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497-506, doi:10.1016/S0140-6736(20)30183-5 (2020).
4 Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 26, 1200-1204, doi:10.1038/s41591-020-0965-6 (2020).
5 Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956-963, doi:10.1126/science.abc7520 (2020).
6 Tilocca, B. et al. Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses. Microbes Infect 22, 188-194, doi:10.1016/j.micinf.2020.04.002 (2020).
7 Burbelo, P. D. et al. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. J Infect Dis 222, 206-213, doi:10.1093/infdis/jiaa273 (2020).
8 Caini, S. et al. Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications. Euro Surveill 25, doi:10.2807/1560-7917.ES.2020.25.23.2000980 (2020).
9 Flude, B. M. et al. Targeting the Complement Serine Protease MASP-2 as a Therapeutic Strategy for Coronavirus Infections. Viruses 13, doi:10.3390/v13020312 (2021).
10 Oliveira, S. C., de Magalhaes, M. T. Q. & Homan, E. J. Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets. Front Immunol 11, 587615, doi:10.3389/fimmu.2020.587615 (2020).
11 Narasimhan, M. et al. Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays among infected, recovered, and vaccinated groups. J Clin Microbiol, doi:10.1128/JCM.00388-21 (2021).
12 Bradley, T. et al. Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med 384, 1959-1961, doi:10.1056/NEJMc2102051 (2021).
13 Lumley, S. F. et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin Infect Dis, doi:10.1093/cid/ciab004 (2021).
14 Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26, 845-848, doi:10.1038/s41591-020-0897-1 (2020).
15 To, K. K. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 20, 565-574, doi:10.1016/S1473-3099(20)30196-1 (2020).
16 Li, Z. et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 92, 1518-1524, doi:10.1002/jmv.25727 (2020).
17 Luo, H. et al. The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients. Front Immunol 12, 632814, doi:10.3389/fimmu.2021.632814 (2021).
18 Chansaenroj, J. et al. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients. Virol J 18, 52, doi:10.1186/s12985-021-01530-2 (2021).
19 Tso, F. Y. et al. Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma. PLoS One 16, e0247640, doi:10.1371/journal.pone.0247640 (2021).
20 Gao, W. et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362, 1895-1896, doi:10.1016/S0140-6736(03)14962-8 (2003).
21 Okada, M. et al. The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice. Vaccine 23, 2269-2272, doi:10.1016/j.vaccine.2005.01.036 (2005).
22 Yao, L. et al. Persistence of Antibody and Cellular Immune Responses in COVID-19 patients over Nine Months after Infection. J Infect Dis, doi:10.1093/infdis/jiab255 (2021).
23 Feng, X. et al. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China. Front Immunol 12, 614436, doi:10.3389/fimmu.2021.614436 (2021).
24 Lin, L. et al. Long-term infection of SARS-CoV-2 changed the body's immune status. Clin Immunol 218, 108524, doi:10.1016/j.clim.2020.108524 (2020).
25 Wheatley, A. K. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun 12, 1162, doi:10.1038/s41467-021-21444-5 (2021).
26 Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371, doi:10.1126/science.abf4063 (2021).
27 Turner, J. S. et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature, doi:10.1038/s41586-021-03647-4 (2021).
28 Vitale, J. et al. Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy. JAMA Intern Med, doi:10.1001/jamainternmed.2021.2959 (2021).